跳至主要内容
临床试验/NCT07062770
NCT07062770招募中不适用

Assessment of Circuit Rebreathing During Continuous Positive Airway Pressure (CPAP) Therapy

Brigham and Women's Hospital2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2025年5月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
13
试验地点
2
主要终点
Change in flow-adjusted average inspired oxygen fraction (FiO₂) during wake.

研究概览

简要总结

The goal of this research is to better understand how different CPAP mask designs affect airflow and rebreathing of exhaled carbon dioxide (CO₂) during sleep in individuals with obstructive sleep apnea (OSA).

详细描述

To understand the existence and severity of circuit rebreathing during treatment with continuous positive airway pressure (CPAP) using different sizes of the exhaust ports in individuals with obstructive sleep apnea (OSA).

Flow-adjusted end-tidal oxygen (PetO2) and carbon dioxide (PetCO2) will be assessed to determine the magnitude of hypoxic load during both wakefulness and sleep. To systematically assess these conditions, the conditions were defined as follows:

  • 5A: 35 L/s exhaust flow with 5 cmH₂O PAP
  • 5B: 23 L/s exhaust flow with 5 cmH₂O PAP
  • 5C: 18 L/s exhaust flow with 5 cmH₂O PAP
  • 5D: 13 L/s exhaust flow with 5 cmH₂O PAP
  • 5E: 8 L/s exhaust flow with 5 cmH₂O PAP
  • 0P: 35 L/s exhaust flow with 0 cmH₂O PAP
  • 10A: 35 L/s exhaust flow with 10 cmH₂O PAP
  • 10B: 23 L/s exhaust flow with 10 cmH₂O PAP
  • 10C: 18 L/s exhaust flow with 10 cmH₂O PAP
  • 10D: 13 L/s exhaust flow with 10 cmH₂O PAP
  • 10E: 8 L/s exhaust flow with 10 cmH₂O PAP Primary endpoint is to evaluate the effect of exhaust flow on flow-adjusted average inspired oxygen fraction (FiO₂) during (1) wakefulness and (2) sleep between 5B vs. 5D.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Other
盲法
Single (Participant)

盲法说明

The exhaust flow and PAP level conditions will be blinded for the participant.

入排标准

年龄范围
21 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Moderate to severe OSA (AHI>20)
  • •Self-reported CPAP users or have previously used CPAP
  • •Self-reported holding pressure of maximum 13 cmH2O (if known)
  • •Age: 21-70
  • •BMI: 18-40 kg/m2

排除标准

  • •Self-reported severe mouth-breathing
  • •Requirement for nocturnal supplemental oxygen or other ventilatory support
  • •Severe cardiovascular or pulmonary disease
  • •Any unstable or acute medical condition
  • •Any additional sleep disorder, including insomnia, except for OSA.

研究组 & 干预措施

5 cmH2O with 18L/s

Experimental

18 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

5 cmH2O with 23L/s

Experimental

23 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

5 cmH2O with 35L/s

Experimental

35 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

5 cmH2O with 35L/s

Experimental

35 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

5 cmH2O with 23L/s

Experimental

23 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

5 cmH2O with 18L/s

Experimental

18 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

5 cmH2O with 13L/s

Experimental

13 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

5 cmH2O with 13L/s

Experimental

13 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

5 cmH2O with 8L/s

Experimental

8 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

5 cmH2O with 8L/s

Experimental

8 L/s exhaust flow with 5 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

0 cmH2O with 35L/s

Placebo Comparator

35 L/s exhaust flow with 0 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

10 cmH2O with 35L/s

Experimental

35 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

10 cmH2O with 35L/s

Experimental

35 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

10 cmH2O with 23L/s

Experimental

23 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

10 cmH2O with 23L/s

Experimental

23 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

10 cmH2O with 18L/s

Experimental

18 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

10 cmH2O with 18L/s

Experimental

18 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

10 cmH2O with 13L/s

Experimental

13 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

10 cmH2O with 13L/s

Experimental

13 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

10 cmH2O with 8L/s

Experimental

8 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Continuous positive airway pressure (CPAP) (Device)

10 cmH2O with 8L/s

Experimental

8 L/s exhaust flow with 10 cmH₂O PAP

干预措施: Mask exhaust port flow (Other)

结局指标

主要结局

Change in flow-adjusted average inspired oxygen fraction (FiO₂) during wake.

时间窗: through study completion, an average of 1 year

Difference in FiO2 between 23L/s vs 13L/s exhaust flow at 5 cmH2O PAP.

Change in flow-adjusted average inspired oxygen fraction (FiO₂) during sleep.

时间窗: through study completion, an average of 1 year

Difference in FiO2 between 23L/s vs 13L/s exhaust flow at 5 cmH2O PAP.

次要结局

  • Impact on hypoxic burden during sleep.(through study completion, an average of 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Atqiya Aishah, Ph.D.

Postdoctoral Research Fellow

Brigham and Women's Hospital

研究点 (2)

Loading locations...

相似试验

Assessment of Circuit Rebreathing During CPAP Therapy | 临床试验